JP2008512473A5 - - Google Patents

Download PDF

Info

Publication number
JP2008512473A5
JP2008512473A5 JP2007531302A JP2007531302A JP2008512473A5 JP 2008512473 A5 JP2008512473 A5 JP 2008512473A5 JP 2007531302 A JP2007531302 A JP 2007531302A JP 2007531302 A JP2007531302 A JP 2007531302A JP 2008512473 A5 JP2008512473 A5 JP 2008512473A5
Authority
JP
Japan
Prior art keywords
ultrafiltration
protein
protein preparation
diafiltration
grams per
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007531302A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008512473A (ja
JP5210633B2 (ja
Filing date
Publication date
Priority claimed from US11/220,362 external-priority patent/US20060051347A1/en
Application filed filed Critical
Publication of JP2008512473A publication Critical patent/JP2008512473A/ja
Publication of JP2008512473A5 publication Critical patent/JP2008512473A5/ja
Application granted granted Critical
Publication of JP5210633B2 publication Critical patent/JP5210633B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2007531302A 2004-09-09 2005-09-08 抗体濃縮法とその治療用製品 Expired - Lifetime JP5210633B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US60909204P 2004-09-09 2004-09-09
US60/609,092 2004-09-09
US11/220,362 2005-09-06
US11/220,362 US20060051347A1 (en) 2004-09-09 2005-09-06 Process for concentration of antibodies and therapeutic products thereof
PCT/US2005/031844 WO2006031560A2 (en) 2004-09-09 2005-09-08 Process for concentration of antibodies and therapeutic products thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011256451A Division JP5426641B2 (ja) 2004-09-09 2011-11-24 抗体濃縮法とその治療用製品

Publications (3)

Publication Number Publication Date
JP2008512473A JP2008512473A (ja) 2008-04-24
JP2008512473A5 true JP2008512473A5 (enExample) 2008-11-06
JP5210633B2 JP5210633B2 (ja) 2013-06-12

Family

ID=35996499

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007531302A Expired - Lifetime JP5210633B2 (ja) 2004-09-09 2005-09-08 抗体濃縮法とその治療用製品
JP2011256451A Expired - Lifetime JP5426641B2 (ja) 2004-09-09 2011-11-24 抗体濃縮法とその治療用製品

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011256451A Expired - Lifetime JP5426641B2 (ja) 2004-09-09 2011-11-24 抗体濃縮法とその治療用製品

Country Status (32)

Country Link
US (6) US20060051347A1 (enExample)
EP (5) EP3805248B1 (enExample)
JP (2) JP5210633B2 (enExample)
KR (2) KR101528970B1 (enExample)
CN (3) CN104961797B (enExample)
AR (1) AR050641A1 (enExample)
AU (1) AU2005285243C1 (enExample)
BR (1) BRPI0515649B8 (enExample)
CA (1) CA2577317C (enExample)
DK (5) DK2292636T3 (enExample)
EC (1) ECSP077282A (enExample)
ES (5) ES2968070T3 (enExample)
FI (4) FI4108259T3 (enExample)
GT (1) GT200500254A (enExample)
HU (4) HUE061899T2 (enExample)
IL (2) IL181372A (enExample)
LT (4) LT4108259T (enExample)
MA (1) MA28991B1 (enExample)
MX (2) MX342788B (enExample)
MY (2) MY150549A (enExample)
NO (1) NO333660B1 (enExample)
NZ (1) NZ553239A (enExample)
PE (1) PE20060816A1 (enExample)
PL (5) PL1786830T3 (enExample)
PT (5) PT4104859T (enExample)
RU (1) RU2390524C2 (enExample)
SG (1) SG177161A1 (enExample)
SI (5) SI2292636T1 (enExample)
TN (1) TNSN07069A1 (enExample)
TW (1) TWI372630B (enExample)
WO (1) WO2006031560A2 (enExample)
ZA (1) ZA200701626B (enExample)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
IL155002A0 (en) * 2000-10-12 2003-10-31 Genentech Inc Reduced-viscosity concentrated protein formulations
DK1610820T4 (da) * 2003-04-04 2013-11-04 Genentech Inc Høj-koncentration antistof- og proteinformuleringer
NZ548871A (en) 2004-01-30 2009-06-26 Shire Pharmaceuticals Ireland Use of arylsulfatase A for treating metachromatic leukodystrophy
EP1758558B1 (en) 2004-05-12 2013-10-16 Baxter International Inc. Oligonucleotide-containing microspheres, their use for the manufacture of a medicament for treating diabetes type 1
DK1765294T3 (da) 2004-05-12 2008-11-10 Baxter Int Nukleinsyremikrokugler samt deres fremstilling og afgivelse
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
EP1909831A4 (en) 2005-06-14 2013-02-20 Amgen Inc SELF-BUFFING PROTEIN FORMULATIONS
EP2007506B1 (en) * 2006-03-31 2014-03-19 Danisco US Inc. Tangential flow filtration apparatuses, systems, and processes for the separation of compounds
PL2631242T3 (pl) 2006-04-04 2023-03-20 Takeda Pharmaceutical Company Limited Sposób zatężania polipeptydu
EP2527364A1 (en) * 2007-03-29 2012-11-28 Abbott Laboratories Crystalline anti-human IL-12 antibodies
EP2170949B1 (en) * 2007-07-17 2012-12-26 F. Hoffmann - La Roche AG Variable tangential flow filtration
WO2009068282A1 (en) * 2007-11-29 2009-06-04 F. Hoffmann-La Roche Ag Immunoglobulin aggregates
TWI661833B (zh) * 2007-11-30 2019-06-11 百慕達商艾伯維生物技術有限責任公司 蛋白質調配物及製造其之方法
US8883146B2 (en) * 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
WO2009129226A1 (en) 2008-04-15 2009-10-22 Talecris Biotherapeutics, Inc. Two-stage ultrafiltration/diafiltration
PL2280999T3 (pl) * 2008-05-15 2018-02-28 Biosys Health Inc. Sposób produkcji frakcji mleka bogatych w immunoglobuliny wydzielnicze
US20110236391A1 (en) * 2008-12-09 2011-09-29 Hanns-Christian Mahler Method for obtaining an excipient-free antibody solution
US8795530B2 (en) * 2009-01-21 2014-08-05 Smartflow Technologies, Inc. Optimization of separation for viscous suspensions
CA2754528A1 (en) * 2009-03-06 2010-09-10 Genetech, Inc. Antibody formulation
JP6159528B2 (ja) * 2009-03-24 2017-07-05 ワイス・エルエルシー 高濃縮のタンパク質治療薬を生成するための膜蒸発
BRPI1012082B1 (pt) * 2009-05-27 2022-08-16 Takeda Pharmaceutical Company Limited Método para preparar uma composição de igg concentrada a partir de plasma
EP2483304B1 (en) 2009-09-29 2016-05-04 F.Hoffmann-La Roche Ag Pre-filtration adjustment of buffer solutes for high concentration immunoglobulin preparation
EP3133083B1 (en) * 2009-10-01 2020-02-19 F. Hoffmann-La Roche AG Multistep final filtration
AU2011212440B2 (en) 2010-02-04 2015-01-22 Csl Behring Ag Immunoglobulin preparation
SG183443A1 (en) 2010-03-01 2012-09-27 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
US10336992B2 (en) 2011-07-08 2019-07-02 Shire Human Genetic Therapies, Inc. Methods for purification of arylsulfatase A
CA2847302C (en) 2011-09-01 2021-02-16 Chugai Seiyaku Kabushiki Kaisha Method for preparing a composition comprising highly concentrated antibodies by ultrafiltration
WO2013096791A1 (en) 2011-12-23 2013-06-27 Genentech, Inc. Process for making high concentration protein formulations
US20130281355A1 (en) 2012-04-24 2013-10-24 Genentech, Inc. Cell culture compositions and methods for polypeptide production
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
WO2014102370A1 (en) * 2012-12-28 2014-07-03 Novo Nordisk A/S High temperature dead end antibody filtration
CN119979504A (zh) 2013-01-09 2025-05-13 武田药品工业株式会社 含用于纯化芳基硫酸酯酶a的方法
DE102013001628A1 (de) 2013-01-30 2014-07-31 Fresenius Medical Care Deutschland Gmbh Verfahren zur Bereitstellung eines Konzentrats
MX383879B (es) 2014-05-13 2025-03-14 Amgen Inc Sistema y métodos de control del proceso para usar con filtros y procesos de filtración.
US10550148B2 (en) * 2014-06-16 2020-02-04 Emd Millipore Corporation Methods for increasing the capacity of flow-through processes
WO2015195452A2 (en) * 2014-06-16 2015-12-23 Emd Millipore Corporation Single-pass filtration systems and processes
EP4144434B1 (en) * 2014-06-16 2024-04-17 EMD Millipore Corporation Single-pass filtration systems and processes
EP2957335B1 (en) * 2014-06-16 2020-05-27 EMD Millipore Corporation Single-pass filtration systems and processes
SG11201508171RA (en) 2014-06-25 2016-01-28 Emd Millipore Corp Compact spiral-wound filter elements, modules and systems
KR102188947B1 (ko) 2014-08-29 2020-12-09 이엠디 밀리포어 코포레이션 잔류물의 재순환을 이용한 싱글 패스 접선 유동 여과 시스템 및 접선 유동 여과 시스템
US10350518B2 (en) 2014-08-29 2019-07-16 Emd Millipore Corporation Processes for filtering liquids using single pass tangential flow filtration systems and tangential flow filtration systems with recirculation of retentate
MA54716A (fr) 2014-10-23 2021-11-17 Amgen Inc Réduction de la viscosité de formulations pharmaceutiques
CA2968915A1 (en) 2014-12-03 2016-06-09 Csl Behring Ag Pharmaceutical product with increased stability comprising immunoglobulins
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
AU2016329034B2 (en) * 2015-09-22 2019-05-23 Pfizer Inc. Method of preparing a therapeutic protein formulation and antibody formulation produced by such a method
EP4066927B1 (en) 2016-06-09 2024-10-09 EMD Millipore Corporation Methods of using radial-path filter elements
TWI767930B (zh) * 2016-08-16 2022-06-21 美商健臻公司 處理包括重組治療性蛋白之流體的方法及其用途
CN118085011A (zh) * 2016-08-17 2024-05-28 勃林格殷格翰国际公司 制备含有生物分子的高度浓缩的液体制剂的方法
AU2017345490B2 (en) 2016-10-21 2022-07-07 Amgen Inc. Pharmaceutical formulations and methods of making the same
JP7377596B2 (ja) 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
CN107952280A (zh) * 2017-11-28 2018-04-24 安徽东方帝维生物制品股份有限公司 一种兽用疫苗无菌超滤浓缩装置及方法
KR102754228B1 (ko) * 2017-12-27 2025-01-14 (주)셀트리온 투석 여과 방법
WO2019199476A1 (en) * 2018-04-12 2019-10-17 Amgen Inc. Methods for making stable protein compositions
TWI846694B (zh) * 2018-05-04 2024-07-01 美商健臻公司 具有過濾系統的灌注式生物反應器
EP3833327A1 (en) * 2018-08-10 2021-06-16 Amgen Inc. Method of preparing an antibody pharmaceutical formulation
EP3837273B1 (en) 2018-08-14 2025-09-24 Bristol-Myers Squibb Company Improved protein recovery
TWI871300B (zh) * 2019-01-28 2025-02-01 美商安進公司 藉由將藥物物質和藥物產品過程整體化的生物製劑製造之連續製造過程
SG11202107441RA (en) * 2019-02-15 2021-08-30 Just Evotec Biologics Inc Automated biomanufacturing systems, facilities, and processes
AU2020323703B2 (en) * 2019-07-31 2022-08-25 Catalent U.K. Swindon Zydis Limited Density flow meter for pharmaceutical formulation dosing
CN111018968B (zh) * 2019-12-16 2021-07-27 兴盟生物医药(苏州)有限公司 一种通过超滤浓缩制备高浓度抗体制剂的方法
JP7338527B2 (ja) * 2020-03-19 2023-09-05 東レ株式会社 体液検体中のアレルゲン特異的ＩｇＥ抗体の検出方法
CN111944046B (zh) * 2020-08-28 2021-04-09 江苏荃信生物医药有限公司 高浓度、低粘度抗人il-23单克隆抗体溶液的制备方法
CN116406369A (zh) * 2020-10-05 2023-07-07 百时美施贵宝公司 用于浓缩蛋白质的方法
WO2022109371A1 (en) 2020-11-23 2022-05-27 Abec, Inc. Filtration systems,components and methods
CA3210568A1 (en) * 2021-03-08 2022-09-15 Boehringer Ingelheim International Gmbh Systems and methods for single pass counter current diafiltration
CN114014929B (zh) * 2021-11-04 2022-07-19 江苏荃信生物医药股份有限公司 一种抗人白介素-33单克隆抗体浓缩溶液的制备方法
IL314394A (en) 2022-02-25 2024-09-01 Amgen Inc Methods for preparing high-concentration liquid drug substances
CN115261193A (zh) * 2022-05-31 2022-11-01 利穗科技(苏州)有限公司 一种生物制品浓缩系统及其工艺
IL318205A (en) * 2022-07-12 2025-03-01 Beigene Switzerland Gmbh Method for preparing a highly concentrated solution of anti-PD1 antibody using ultrafiltration/diafiltration (UF/DF)
CN115873064A (zh) * 2022-09-27 2023-03-31 英脉生物医药(杭州)有限公司 高浓度蛋白样品的制备装置及方法
AU2024260197A1 (en) * 2023-04-25 2025-11-13 Enzene Biosciences Limited In line cleaning in place process for alternating tangential flow filter
US12030959B1 (en) 2023-07-05 2024-07-09 Genentech, Inc. Anti-IgE antibody therapy for multiple food allergies
CA3237624A1 (en) 2023-07-28 2025-04-24 Genentech Inc New uses of omalizumab
WO2025101602A1 (en) 2023-11-07 2025-05-15 Amgen Inc. Methods of analyzing amino acid content of a therapeutic protein

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5625616B2 (enExample) 1973-10-08 1981-06-13
FR2459619B1 (fr) 1979-06-26 1983-07-29 Agronomique Inst Nat Rech Procede pour l'obtention a partir de lactoserum, d'un produit enrichi en alpha-lactalbumine et applications dudit procede
US4362661A (en) 1979-08-09 1982-12-07 Teijin Limited Immunoglobulin composition having a high monomer content, and process for production thereof
US4374763A (en) 1979-09-17 1983-02-22 Morishita Pharmaceutical Co., Ltd. Method for producing gamma-globulin for use in intravenous administration and method for producing a pharmaceutical preparation thereof
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
ZA847349B (en) 1983-10-05 1985-04-24 Solco Basel Ag Process for the preparation of a biologically active extract
US4786501A (en) * 1985-07-15 1988-11-22 International Minerals & Chemical Corp. Cylindrical implants for the controlled release of growth hormones
US4756696A (en) 1985-12-06 1988-07-12 Amp Incorporated Solder joint inspection feature for surface mount connectors
GB8628104D0 (en) * 1986-11-25 1986-12-31 Connaught Lab Pasteurization of immunoglobin solutions
JPS6485829A (en) 1987-09-29 1989-03-30 Aisin Aw Co Transmission for four-wheel drive vehicle
JPH01268646A (ja) 1988-04-20 1989-10-26 Meiji Milk Prod Co Ltd 抗腫瘍剤
GB2218703B (en) 1988-05-10 1992-10-28 Sumitomo Chemical Co Human monoclonal antibody to p.aeruginosa: its production and use
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US4897465A (en) 1988-10-12 1990-01-30 Abbott Laboratories Enrichment and concentration of proteins by ultrafiltration
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
AU4803890A (en) 1988-12-15 1990-07-10 Invitron Corporation Use of basic amino acids to solubilize immunoglobulins
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US5177194A (en) * 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
NL9001650A (nl) 1990-07-19 1992-02-17 Ver Coop Melkind Werkwijze voor de bereiding van een melkeiwit-isolaat.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5256294A (en) 1990-09-17 1993-10-26 Genentech, Inc. Tangential flow filtration process and apparatus
JP2916947B2 (ja) 1990-11-28 1999-07-05 興和株式会社 Ｃｐｂ―ｉの安定化方法及び製剤組成物
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
JP2907603B2 (ja) * 1991-09-09 1999-06-21 雪印乳業株式会社 新規生理活性ペプチド、該活性ペプチドを有効成分とする胃酸分泌抑制剤、抗潰瘍剤及び飲食品
US6270757B1 (en) 1994-04-21 2001-08-07 Genetics Institute, Inc. Formulations for IL-11
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
US5580856A (en) 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5707678A (en) 1995-04-12 1998-01-13 Galagen Inc. Method for microfiltration of milk or colostral whey
JP4312259B2 (ja) 1995-04-27 2009-08-12 アムジェン フレモント インク． 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
MX9800684A (es) * 1995-07-27 1998-04-30 Genentech Inc Formulacion de proteinas liofilizadas isotonicas estables.
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
DE19543737A1 (de) 1995-11-24 1997-05-28 Hoechst Ag Verfahren zur Ultrafiltration von Peptide oder Proteine enthaltender biologischer Matrices
US5770700A (en) 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
KR100236393B1 (ko) 1996-02-02 1999-12-15 나까니시 히로유끼 사람성장호르몬을 함유하는 의약제제
TWI240627B (en) 1996-04-26 2005-10-01 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
GB9610992D0 (en) 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
DE69738539T2 (de) 1996-12-03 2009-03-26 Amgen Fremont Inc. Vollkommen humane Antikörper die EGFR binden
US5994511A (en) 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
US6172213B1 (en) 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
JP2001516599A (ja) * 1997-09-22 2001-10-02 セプラジェン コーポレーション ホエータンパク質の逐次分離およびその配合物
RU2140287C1 (ru) * 1998-08-25 1999-10-27 Государственное унитарное предприятие "Иммунопрепарат" Способ получения альбумина
WO2000024266A2 (en) 1998-10-26 2000-05-04 Galagen, Inc. Soy and immunoglobulin compositions
JP2000247903A (ja) 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
WO2001003515A1 (en) 1999-07-07 2001-01-18 New Zealand Co-Operative Dairy Company Limited Method of obtaining protein isolates and concentrates from colostrum
CN100389821C (zh) 1999-10-04 2008-05-28 希龙公司 稳定化的含多肽的液体药物组合物
WO2002013860A1 (en) * 2000-08-11 2002-02-21 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing preparations
IL155002A0 (en) 2000-10-12 2003-10-31 Genentech Inc Reduced-viscosity concentrated protein formulations
ES2184594B1 (es) 2001-01-17 2004-01-01 Probitas Pharma Sa Procedimiento para la produccion de gammaglobulina g humana inactivada de virus.
ATE454137T1 (de) 2001-07-25 2010-01-15 Facet Biotech Corp Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
US20030138417A1 (en) 2001-11-08 2003-07-24 Kaisheva Elizabet A. Stable liquid pharmaceutical formulation of IgG antibodies
EP2322165A1 (en) * 2001-11-13 2011-05-18 Genentech, Inc. Apo2 ligand/TRAIL formulations
US20030180287A1 (en) 2002-02-27 2003-09-25 Immunex Corporation Polypeptide formulation
CN1671741A (zh) * 2002-06-21 2005-09-21 拜奥根Idec公司 浓缩抗体的缓冲剂制剂及其使用方法
WO2004042012A2 (en) * 2002-11-01 2004-05-21 Bayer Healthcare Llc Process for concentration of macromolecules
GB0229444D0 (en) 2002-12-18 2003-01-22 Royal Free Hampstead Nhs Trust Diagnostic method and assay kit
CA2516836A1 (en) * 2003-02-24 2004-09-10 Gtc Biotherapeutics, Inc. Methods of tangential flow filtration and an apparatus therefore
DK1610820T4 (da) 2003-04-04 2013-11-04 Genentech Inc Høj-koncentration antistof- og proteinformuleringer
EP1709077A1 (en) 2004-01-30 2006-10-11 Suomen Punainen Risti Veripalvelu Process for the manufacture of virus safe immunoglobulin
US20080247991A1 (en) 2004-02-26 2008-10-09 Trout Bernhardt L Solution Additives For the Attenuation of Protein Aggregation
WO2006018956A1 (ja) 2004-08-19 2006-02-23 Electronic Navigation Research Institute, An Independent Administrative Institution 誘電体レンズを用いた装置
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
JP6044754B2 (ja) 2012-01-19 2016-12-14 株式会社ジェイテクト クラッチプレートおよびその製造方法
WO2019035815A1 (en) 2017-08-16 2019-02-21 O&M Halyard International Unlimited Company METHOD AND SYSTEM FOR FASTENING ATTACHES IN A METHOD FOR MANUFACTURING FACIAL MASKS

Similar Documents

Publication Publication Date Title
JP2008512473A5 (enExample)
RU2390524C2 (ru) Способ концентрирования препаратов антител
JP3746223B2 (ja) 蛋白質溶液から蛋白質凝集体及びウイルスを除去する方法
AR121861A2 (es) MÉTODO PARA PREPARAR UNA COMPOSICIÓN DE IgG ENRIQUECIDA A PARTIR DE PLASMA
JP5755136B2 (ja) 高濃度モノクローナル抗体溶液中のウイルス除去方法
JP6956824B2 (ja) 生体高分子ユニットおよびウイルスを液体から分離するための方法
JP2013516429A5 (enExample)
JP2013516432A5 (enExample)
KR101376410B1 (ko) 중공 섬유 막을 이용한 전단 민감성 생체중합체 농축 방법
JP6985282B2 (ja) ７型コラーゲンの精製方法
JP2013527201A5 (enExample)
US6773600B2 (en) Use of a clathrate modifier, to promote passage of proteins during nanofiltration
Zhang et al. Selective separation of proteins by microfiltration with formed-in-place membranes
JP5124475B2 (ja) 粉末の形態のバンコマイシンから着色不純物を除去する方法
DK2483305T3 (en) MULTI-STEP-END FILTERING Immunoglobulin
JP2012112930A (ja) 高分子量物質の精製方法
US20040116676A1 (en) Methods for removal of contaminants from blood product solutions
CN102988989B (zh) 一种代血浆的膜分离精制提纯方法
JP2012214408A (ja) 澄明液中に分散した不純物凝集体を除去することによるタンパク質の精製方法
HK40033015A (en) Methods of concentrating shear-sensitive biopolymers
JP5933265B6 (ja) 中空糸膜を使用しての剪断感受性バイオポリマーを濃縮する方法
KR101744134B1 (ko) 나노 여과 공정을 포함한 l-핵산 유도체의 제조 방법
WO2004089403A1 (ja) アルブミン凝集体及び／または不純蛋白質の除去方法
Ng et al. Filter applications in product recovery processes
JPH0656897A (ja) オボトランスフェリンの分離方法